Poland· PL-100396986
Bortezomib Krka
A bortezomib product containing bortezomibum, registered in Poland by Krka, d.d., Novo mesto. The same ATC class is registered in 3 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Bortezomib is registered in 3 of 19 countries.
Countries holding a registration under ATC L01XX32 (bortezomib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 2 of them publish a price we can compare per daily dose
Bortezomib · ATC L01XX32
3 / 19 countries
- Belgiumprice
- Ireland
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Bortezomibum
- Manufacturer
- Krka, d.d., Novo mesto
- Country
- Poland (PL)
- ATC code
- L01XX32
- ATC class
- Bortezomib
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- June 28, 2026
Packs & prices · 1
- gtin03838989709280
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
587 interactions on record for bortezomib.
Graded by severity as the source publishes them — 45 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Bortezomib · interactions on record
587 records
- 45 severe
- 250 moderate
- 66 minor
- 226 info
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- RifampicinJ04AB02severe
- RifabutinJ04AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Bortezomib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainBORTEZOMIB ACCORD 3,5 MG POLVO PARA SOLUCION INYECTABLE EFGAccord Healthcare S.L.U.
- United KingdomBortezomib 3.5mg powder for solution for injection vialsTillomed Laboratories Ltd
- SwedenBortezomib Accord 3,5 mg Pulver till injektionsvätska, lösningAccord Healthcare S.L.U.
- IcelandBortezomib AccordAccord Healthcare S.L.U.
- CzechiaBORTEZOMIB ACCORDAccord Healthcare S.L.U., Barcelona
- FinlandBortezomib EbeweEbewe Pharma Ges.m.b.H. Nfg.KG
- NorwayBortezomib mylanMylan
- BelgiumBortezomib Baxter 3.5 mgBaxter Holding
Authorised across Europe · EMA
The same active substance is authorised in 28 EEA countries. Names it is sold under:
- Austria · Abormib, Bortezomib Ever Pharma
- Belgium · Bortezomib Eg, Bortezomib Eugia
- Bulgaria · Bortezomib Ever Pharma, Бортезомиб Актавис
- Cyprus · Bortezomib Pharmazac, Bortezomib Stada
- Czechia · Bortezomib Ever Pharma, Bortezomib Msn
- Germany · Bortezomib, Bortezomib Amarox
- Denmark · Bortezomib Actavis, Bortezomib Ever Pharma
- Spain · Bortezomib Aurovitas, Bortezomib Combix
- Finland · Bortezomib Avansor, Bortezomib Ever Pharma
- France · Bortezomib, Bortezomib Arrow
- United Kingdom (Northern Ireland) · Bortezomib, Bortezomib Accord
- Greece · Bortezomib Pharmazac, Bortezomib Sandoz
- Croatia · Bortezomib Alpha-Medical, Bortezomib Ever Pharma
- Hungary · Bortezomib Ever Pharma, Bortezomib Msn
- Ireland · Bortezomib Aspire Pharma (Malta), Bortezomib Biotech Pharma Limited
- Iceland · Bortezomib Accord, Bortezomib Actavis
- Italy · Bortezomib Aurobindo, Bortezomib Dr. Reddy’s
- Liechtenstein · Bortezomib Accord, Bortezomib Fresenius Kabi
- Luxembourg · Bortezomib Eg
- Latvia · Bortezomib Tzf
- Malta · Bortezomib Clonmel, Bortezomib Dr. Reddy’s
- Netherlands · Bortezomib Amarox, Bortezomib Cf
- Norway · Bortezomib Accord, Bortezomib Ever Pharma
- Portugal · Bortezomib Ever Pharma, Bortezomib Extrovis
- Romania · Bortezomib, Bortezomib Dr. Reddy’s
- Sweden · Bortezomib Avansor, Bortezomib Ever Pharma
- Slovenia · Bortezomib Actavis, Bortezomib Ever Pharma
- Slovakia · Bortezomib Ever Pharma, Bortezomib Glenmark
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c0d8f0e0-484d-4429-b51a-138a5e3007c7 GET /v1/drugs/c0d8f0e0-484d-4429-b51a-138a5e3007c7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania roztworu do wstrzykiwań",
"source": "urpl",
"strength": "3,5 mg",
"packaging": "03838989709280 ¦ Rpz ¦ 132653\n1 fiol. 3,5 mg",
"substance": "Bortezomibum 3.5 mg",
"common_name": "Bortezomibum",
"pl_product_id": "100396986",
"pozwolenie_nr": "25335",
"auth_procedure": "DCP",
"authorisation_validity": "2023-06-29"
}See everything about bortezomib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.